MaxCyte

MXCTPhase 1

MaxCyte is a global leader in non-viral cell engineering, offering its proprietary ExPERT electroporation platform to biopharmaceutical companies and academic institutions. With over 25 years of expertise, its technology is validated in more than 70 clinical trials and is used in the manufacturing of a commercial cell therapy. The company's strategic, partnership-driven model provides comprehensive scientific, technical, and regulatory support, aiming to de-risk and accelerate partners' paths from discovery to commercialization.

Market Cap

$81.6M

MXCT · Stock Price

USD 0.776.35 (-89.25%)

Historical price data

AI Company Overview

Technology Platform

The ExPERT platform utilizes proprietary Flow Electroporation® technology for high-efficiency, scalable, non-viral transfection of a wide variety of cell types, from discovery to GMP-compliant commercial manufacturing.

Pipeline Snapshot

1 drug in pipeline

Drug	Indication	Stage
MCY-M11 + Cyclophosphamide	Peritoneal Mesothelioma	Phase 1

Opportunities

Growth is driven by the expansion of the cell and gene therapy market, increased adoption of non-viral manufacturing methods, and the progression of partner therapies into late-stage trials and commercialization, which triggers milestone and royalty payments.

Risk Factors

Key risks include dependency on partner success, potential technological disruption from alternative delivery methods, intense competition from larger life science tools companies, and regulatory or market delays in the broader cell therapy sector.

Competitive Landscape

Main competitors include Lonza (Nucleofector), Thermo Fisher Scientific, and Bio-Rad. MaxCyte differentiates through its clinically and commercially validated scalable Flow Electroporation® technology and its comprehensive, partnership-driven support model that de-risks therapy development.